@article{shiraki_short-term_2009,
	title = {Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study},
	volume = {27},
	issn = {0914-8779},
	shorttitle = {Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis},
	doi = {10.1007/s00774-008-0034-6},
	abstract = {The effect of vitamin K(2) (menatetrenone) on bone turnover was investigated in postmenopausal patients with osteoporosis. A 6-month open-label, randomized prospective study was conducted in 109 patients. The control group (n = 53) received calcium aspartate (133.8 mg of elemental calcium daily), while the menatetrenone group (n = 56) received 45 mg of menatetrenone daily for 6 months. Serum and urinary levels of bone turnover markers were monitored. The serum level of undercarboxylated osteocalcin (uc-OC) was significantly lower (P {\textless} 0.001) in the menatetrenone group than in the control group (at 1 month), while there was a higher level of osteocalcin containing gamma-carboxylated glutamic acid (Gla-OC) in the menatetrenone group than the control group (P = 0.018). Significant differences of uc-OC and Gla-OC between the two groups were observed from 1 month onward. In addition, a higher level of intact osteocalcin was found in the menatetrenone group compared with the control group after 6 months (P = 0.006). Assessment of bone resorption markers showed that menatetrenone therapy was associated with significantly higher urinary N-telopeptide of type I collagen (NTX) excretion compared with the control group after 6 months, while there was no significant difference of urinary deoxypyridinoline excretion between the two groups. In conclusion, one month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin, while urinary NTX excretion was increased after 6 months of treatment. Further investigations are required to determine whether the effects of menatetrenone on bone turnover are associated with fracture prevention.},
	language = {eng},
	number = {3},
	journal = {Journal of Bone and Mineral Metabolism},
	author = {Shiraki, Masataka and Itabashi, Akira},
	year = {2009},
	pmid = {19172219},
	keywords = {Aged, Biomarkers, Bone Density, Bone Remodeling, Calcium, Female, Hemostatics, Hormones, Humans, Lumbar Vertebrae, Osteocalcin, Osteoporosis, Postmenopausal, Protein Processing, Post-Translational, Time Factors, Treatment Outcome, Vitamin K 2},
	pages = {333--340},
}

{"_id":"4fYXKy7TPKBKwgrDc","bibbaseid":"shiraki-itabashi-shorttermmenatetrenonetherapyincreasesgammacarboxylationofosteocalcinwithamoderateincreaseofboneturnoverinpostmenopausalosteoporosisarandomizedprospectivestudy-2009","author_short":["Shiraki, M.","Itabashi, A."],"bibdata":{"bibtype":"article","type":"article","title":"Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study","volume":"27","issn":"0914-8779","shorttitle":"Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis","doi":"10.1007/s00774-008-0034-6","abstract":"The effect of vitamin K(2) (menatetrenone) on bone turnover was investigated in postmenopausal patients with osteoporosis. A 6-month open-label, randomized prospective study was conducted in 109 patients. The control group (n = 53) received calcium aspartate (133.8 mg of elemental calcium daily), while the menatetrenone group (n = 56) received 45 mg of menatetrenone daily for 6 months. Serum and urinary levels of bone turnover markers were monitored. The serum level of undercarboxylated osteocalcin (uc-OC) was significantly lower (P \\textless 0.001) in the menatetrenone group than in the control group (at 1 month), while there was a higher level of osteocalcin containing gamma-carboxylated glutamic acid (Gla-OC) in the menatetrenone group than the control group (P = 0.018). Significant differences of uc-OC and Gla-OC between the two groups were observed from 1 month onward. In addition, a higher level of intact osteocalcin was found in the menatetrenone group compared with the control group after 6 months (P = 0.006). Assessment of bone resorption markers showed that menatetrenone therapy was associated with significantly higher urinary N-telopeptide of type I collagen (NTX) excretion compared with the control group after 6 months, while there was no significant difference of urinary deoxypyridinoline excretion between the two groups. In conclusion, one month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin, while urinary NTX excretion was increased after 6 months of treatment. Further investigations are required to determine whether the effects of menatetrenone on bone turnover are associated with fracture prevention.","language":"eng","number":"3","journal":"Journal of Bone and Mineral Metabolism","author":[{"propositions":[],"lastnames":["Shiraki"],"firstnames":["Masataka"],"suffixes":[]},{"propositions":[],"lastnames":["Itabashi"],"firstnames":["Akira"],"suffixes":[]}],"year":"2009","pmid":"19172219","keywords":"Aged, Biomarkers, Bone Density, Bone Remodeling, Calcium, Female, Hemostatics, Hormones, Humans, Lumbar Vertebrae, Osteocalcin, Osteoporosis, Postmenopausal, Protein Processing, Post-Translational, Time Factors, Treatment Outcome, Vitamin K 2","pages":"333–340","bibtex":"@article{shiraki_short-term_2009,\n\ttitle = {Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study},\n\tvolume = {27},\n\tissn = {0914-8779},\n\tshorttitle = {Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis},\n\tdoi = {10.1007/s00774-008-0034-6},\n\tabstract = {The effect of vitamin K(2) (menatetrenone) on bone turnover was investigated in postmenopausal patients with osteoporosis. A 6-month open-label, randomized prospective study was conducted in 109 patients. The control group (n = 53) received calcium aspartate (133.8 mg of elemental calcium daily), while the menatetrenone group (n = 56) received 45 mg of menatetrenone daily for 6 months. Serum and urinary levels of bone turnover markers were monitored. The serum level of undercarboxylated osteocalcin (uc-OC) was significantly lower (P {\\textless} 0.001) in the menatetrenone group than in the control group (at 1 month), while there was a higher level of osteocalcin containing gamma-carboxylated glutamic acid (Gla-OC) in the menatetrenone group than the control group (P = 0.018). Significant differences of uc-OC and Gla-OC between the two groups were observed from 1 month onward. In addition, a higher level of intact osteocalcin was found in the menatetrenone group compared with the control group after 6 months (P = 0.006). Assessment of bone resorption markers showed that menatetrenone therapy was associated with significantly higher urinary N-telopeptide of type I collagen (NTX) excretion compared with the control group after 6 months, while there was no significant difference of urinary deoxypyridinoline excretion between the two groups. In conclusion, one month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin, while urinary NTX excretion was increased after 6 months of treatment. Further investigations are required to determine whether the effects of menatetrenone on bone turnover are associated with fracture prevention.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Journal of Bone and Mineral Metabolism},\n\tauthor = {Shiraki, Masataka and Itabashi, Akira},\n\tyear = {2009},\n\tpmid = {19172219},\n\tkeywords = {Aged, Biomarkers, Bone Density, Bone Remodeling, Calcium, Female, Hemostatics, Hormones, Humans, Lumbar Vertebrae, Osteocalcin, Osteoporosis, Postmenopausal, Protein Processing, Post-Translational, Time Factors, Treatment Outcome, Vitamin K 2},\n\tpages = {333--340},\n}\n\n","author_short":["Shiraki, M.","Itabashi, A."],"key":"shiraki_short-term_2009","id":"shiraki_short-term_2009","bibbaseid":"shiraki-itabashi-shorttermmenatetrenonetherapyincreasesgammacarboxylationofosteocalcinwithamoderateincreaseofboneturnoverinpostmenopausalosteoporosisarandomizedprospectivestudy-2009","role":"author","urls":{},"keyword":["Aged","Biomarkers","Bone Density","Bone Remodeling","Calcium","Female","Hemostatics","Hormones","Humans","Lumbar Vertebrae","Osteocalcin","Osteoporosis","Postmenopausal","Protein Processing","Post-Translational","Time Factors","Treatment Outcome","Vitamin K 2"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/groups/46698/items?key=KhA4GoMeOvxPn5tlpemkMrP3&format=bibtex&limit=100","dataSources":["eNLhE9u3rjhQrhN5R"],"keywords":["aged","biomarkers","bone density","bone remodeling","calcium","female","hemostatics","hormones","humans","lumbar vertebrae","osteocalcin","osteoporosis","postmenopausal","protein processing","post-translational","time factors","treatment outcome","vitamin k 2"],"search_terms":["short","term","menatetrenone","therapy","increases","gamma","carboxylation","osteocalcin","moderate","increase","bone","turnover","postmenopausal","osteoporosis","randomized","prospective","study","shiraki","itabashi"],"title":"Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study","year":2009}